Bimonthly fluorouracil in elderly patients with metastatic colorectal cancer: a report of 50 patients.

被引:13
|
作者
Mabro, M [1 ]
Gilles-Amar, V [1 ]
Louvet, C [1 ]
Carola, E [1 ]
Maindrault-Goebel, F [1 ]
de Gramont, A [1 ]
Krulik, M [1 ]
机构
[1] Hop St Antoine, Serv Med Interne Oncol, F-75012 Paris, France
来源
REVUE DE MEDECINE INTERNE | 1999年 / 20卷 / 10期
关键词
chemotherapy; colorectal cancer; elderly; 5; fluorouracil; leucovorin;
D O I
10.1016/S0248-8663(00)80091-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose, - Recent advances in the management of colorectal cancer have improved the quality of life and the survival of patients treated with chemotherapy. In order to define the contribution of chemotherapy in elderly patients, we studied the tolerance and the efficacy of first-line chemotherapy in patients with metastatic colorectal cancer. Methods. - Patients aged oiler 75 years received, as outpatient therapy, a bimonthly 48 h leucovorin and fluorouracil regimen. Evaluation was assessed every six cycles (i.e., three months). Results, - Fifty patients were studied: 28 males and 22 females, aged between 75 to 87 years, 37 with colon cancer and 13 with rectal cancer. Among 45 patients capable of being evaluated, the response rate was 44%, with six complete responses (13%) and 14 partial responses (31%). Eighteen patients had stable disease (40%) and seven patients progressive disease (16%). Median progression;free survival was 8.8 months and median survival 16.4 months. Grade 3 to 4 toxicity occurred in 20% of the patients. Performance status improved in 56% of the patients. Conclusion, - The bimonthly regimen is well tolerated in elderly patients and appears to prolong survival as well in younger patients. (C) 1999 Editions scientifiques et medicales Elsevier SAS.
引用
收藏
页码:863 / 868
页数:6
相关论文
共 50 条
  • [21] Bleeding after bevacizumab treatment in patients with metastatic colorectal cancer
    Cao, Dan
    Guo, Chun-hong
    Liu, Jie-wei
    Yang, Xi
    Li, Qiu
    TUMORI JOURNAL, 2015, 101 (01): : 46 - 51
  • [22] Feasibility of Modified FOLFOX in Elderly Patients Aged ≥80 Years with Metastatic Gastric Cancer or Colorectal Cancer
    Lim, Kyu-Hyoung
    Lee, Hui-Young
    Park, Sung Bae
    Song, Seo-Young
    ONCOLOGY, 2017, 93 (02) : 115 - 121
  • [23] Bevacizumab treatment in the elderly patient with metastatic colorectal cancer
    Di Bartolomeo, Maria
    Maggi, Claudia
    Ricchini, Francesca
    Pietrantonio, Filippo
    Iacovelli, Roberto
    de Braud, Filippo
    Inno, Alessandro
    CLINICAL INTERVENTIONS IN AGING, 2015, 10 : 127 - 133
  • [24] The Place of Targeted Agents in the Treatment of Elderly Patients with Metastatic Colorectal Cancer
    Matikas, Alexios
    Asimakopoulou, Natalia
    Georgoulias, Vassilis
    Souglakos, John
    CANCERS, 2015, 7 (01): : 439 - 449
  • [25] Treatment of Metastatic Colorectal Cancer in the Elderly
    Nguyen, Hong L.
    Hwang, Jimmy
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2009, 10 (5-6) : 287 - 295
  • [26] Phase 2 Study of Modified Irinotecan and Bolus 5-Fluorouracil/l-Leucovorin in Japanese Metastatic Colorectal Cancer Patients
    Baba, Eishi
    Fujishima, Hiromitsu
    Makiyama, Akitaka
    Uchino, Keita
    Tanaka, Risa
    Esaki, Taito
    Kusaba, Hitoshi
    Mitsugi, Kenji
    Nakano, Shuji
    Akashi, Koichi
    ADVANCES IN THERAPY, 2012, 29 (03) : 287 - 296
  • [27] Cetuximab efficacy and safety in a retrospective cohort of elderly patients with heavily pretreated metastatic colorectal cancer
    Bouchahda, M.
    Macarulla, T.
    Spano, J. P.
    Bachet, J. B.
    Lledo, G.
    Andre, T.
    Landi, B.
    Tabernero, J.
    Karaboue, A.
    Domont, J.
    Levi, F.
    Rougier, P.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2008, 67 (03) : 255 - 262
  • [28] The efficacy and safety of capecitabine plus bevacizumab combination as first-line treatment in elderly metastatic colorectal cancer patients
    Ozcelik, M.
    Odabas, H.
    Ercelep, O.
    Yuksel, S.
    Mert, A. G.
    Aydin, D.
    Surmeli, H.
    Isik, D.
    Isik, S.
    Oyman, A.
    Ustaalioglu, B. B. Oven
    Aliustaoglu, M.
    Gumus, M.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2016, 18 (06) : 617 - 624
  • [29] Impact of the addition of bevacizumab, oxaliplatin, or irinotecan to fluoropyrimidin in the first-line treatment of metastatic colorectal cancer in elderly patients
    Landre, Thierry
    Maillard, Emilie
    Taleb, Cherifa
    Ghebriou, Djamel
    Des Guetz, Gaetan
    Zelek, Laurent
    Aparicio, Thomas
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2018, 33 (08) : 1125 - 1130
  • [30] Meta-analysis of molecular targetted agents in the treatment of elderly patients with metastatic colorectal cancer: does the age matter?
    Zhao, ChuanJie
    Li, ShuLiang
    Liu, Qiang
    JOURNAL OF CHEMOTHERAPY, 2016, 28 (04) : 321 - 327